Hitachi to Develop 'Confidential AI Platform' to Accelerate Open Innovation in AI Drug Discovery. Full-Scale Co-Creation with MOLCURE Toward Service Provision

MOLCURE was established in 2013 with the aim of building the world's most superior biopharmaceutical design platform. Its AI drug discovery platform is built upon a proprietary large language model and high-quality experimental data obtained from its in-house bio-laboratory, enabling the design of diverse and high-quality antibodies and peptides. By partnering with innovative pharmaceutical companies, we contribute to the development of medicines that improve the lives of patients worldwide.